Involving Antigen-antibody Binding, Specific Binding Protein Assay Or Specific Ligand-receptor Binding Assay Patents (Class 435/7.1)
  • Patent number: 11925735
    Abstract: Embodiments of apparatuses and methods for determining a positioning of sensors in a wound dressing are disclosed. In some embodiments, a wound monitoring and/or therapy system can include a wound dressing and a plurality of sensors configured to measure one or more wound characteristics. The wound monitor system can also include at least one positioning device configured to indicate position and/or orientation in the wound of a sensor of the plurality of sensors. In some embodiments, a detector can be configured to determine, based on the positioning data, the position and/or orientation in the wound of the sensor of the plurality of sensors. In some embodiments, the plurality of sensors can be positioned on a strip or string of material in communication with the positioning device.
    Type: Grant
    Filed: August 10, 2018
    Date of Patent: March 12, 2024
    Inventors: Philip Gowans, Allan Kenneth Frazer Grugeon Hunt, Marcus Damian Phillips, Damian Smith, Charlotte Urwin
  • Patent number: 11926660
    Abstract: The present disclosure encompasses compositions and methods for effectively treating at least one symptom or sign of Aß plaque or cerebral amyloid angiopathy (CAA) associated symptoms, or for decreasing amyloid plaque load or CAA load. The method comprises administering an effective amount of an anti-ApoE antibody to a mammalian subject, such as to a human.
    Type: Grant
    Filed: August 24, 2021
    Date of Patent: March 12, 2024
    Assignee: Washington University
    Inventors: David Holtzman, Hong Jiang, Thu Nga Bien-Ly, Mark S. Dennis, Jing Guo, Adam P. Silverman, Ryan J. Watts, Yin Zhang
  • Patent number: 11925676
    Abstract: The invention features combination therapies using an IL-15-based superagonist complex and an antibody to effectively treat subjects with cancer and infectious diseases.
    Type: Grant
    Filed: February 27, 2023
    Date of Patent: March 12, 2024
    Assignee: Altor Bioscience, LLC.
    Inventors: Bai Liu, Peter Rhode, Wenxin Xu, Hing C. Wong
  • Patent number: 11927651
    Abstract: A system for one-sided measuring a presence of magnetic particles in a probe volume comprises a one-sided coil assembly and a current controller, wherein the one-sided coil assembly is arranged around a central coil assembly axis for generating a rotating magnetic field distribution and comprises at least 3, preferably at least 4, circumferentially distributed coil assembly sectors, wherein the current controller is configured to generate a time varying current in each of said coil assembly sectors, said time varying current comprising a periodic modulation with a rotation frequency and phase shifted between adjacent coil assembly sectors to generate a magnetic field rotating in a plane perpendicular to the coil assembly axis, said magnetic field rotating with a rotation frequency associated with a frequency of said periodic modulation, and wherein the system is configured for measuring said presence of magnetic particles in said probe volume with said one-sided coil assembly.
    Type: Grant
    Filed: February 21, 2020
    Date of Patent: March 12, 2024
    Assignee: Julius-Maximilians-Universität Würzburg
    Inventors: Patrick Vogel, Martin Rückert
  • Patent number: 11926876
    Abstract: Embodiments of the present invention relate to a combination of experimental and computational workflows that allow characterization of skin and subcutaneous tissue microbial flora and its associated metabolome, aiming to first evaluate an individual's skin and subcutaneous tissue to determine if any skin condition is as a result of an imbalance or absence of commensal or mutualistic microorganisms or their associated metabolites. In particular, embodiments of the methods and the associated computational platform provided herein relate to conducting a customized or personalized test and obtaining customized or personalized information regarding the skin and subcutaneous tissue flora and its associated metabolome there from. This may be accomplished by simultaneously identifying hundreds of microorganisms or metabolites on an individual's skin and subcutaneous tissue and comparing the resulting profile to a previously compiled healthy profile from our database of skin profiles.
    Type: Grant
    Filed: March 9, 2018
    Date of Patent: March 12, 2024
    Assignee: PRODERMIQ, INC.
    Inventors: Sasan Amini, Dana Hosseini
  • Patent number: 11920135
    Abstract: Methods and compositions for treating cancer, e.g., prostate cancer, using a combination of P-Rex1 or Rac1 inhibitors and VEGF/VEGFR-targeted therapy.
    Type: Grant
    Filed: February 4, 2021
    Date of Patent: March 5, 2024
    Assignee: University of Massachusetts
    Inventors: Hira Lal Goel, Arthur M. Mercurio
  • Patent number: 11918315
    Abstract: This disclosure generally relates to systems and methods for facilitating determination of morphology (e.g., shape) and structure (e.g., size, rigidity) and/or penetrating channels (e.g., microchannels) of occlusions (e.g., clots, fluid obstructions, tumors, chronic total occlusions) involving magnetic particles (e.g., nanoparticles, microparticles) controlled by an external magnetic control system.
    Type: Grant
    Filed: May 2, 2019
    Date of Patent: March 5, 2024
    Assignee: Pulse Therapeutics, Inc.
    Inventors: Brian L. Kidd, Sean C. Morris, Michael E. Sabo
  • Patent number: 11921041
    Abstract: Exemplified methods and systems facilitate presentation of data derived from measurements of endotoxins in fluid samples. In particular, the exemplified methods and systems facilitate presentation of such measurements in a graphical user interface and/or in a report for endotoxin concentrations in a fluid sample. The presentation facilitates a unified and intuitive graphic visualization that are presented within a single interactive interface and/or report.
    Type: Grant
    Filed: March 9, 2020
    Date of Patent: March 5, 2024
    Assignee: BL Technologies, Inc.
    Inventors: Sukmi Ledru, Krzysztof Franaszczuk, Jesse Manley, David Kremer, Vamsi Panuganti, Jeremiah Teague, Yan Le, Michael Scaer
  • Patent number: 11920172
    Abstract: The present invention relates to chimeric (preferably, bifunctional) compounds, compositions comprising those compounds and methods of treating cancer in a patient or subject, especially including metastatic cancer where cancer cells exhibit overexpression (heightened expression) of cell surface urokinase-type plasminogen activator receptor (urokinase receptor) compared to normal (non-cancerous) cells. The compounds preferably covalently bind to the urokinase receptor and recruit native antibodies of the patient or subject where the antibodies can selectively degrade and/or deactivate targeted cancer cells through antibody-dependent cellular phagocytosis and/or antibody-dependent cellular cytotoxicity (ADCC) against a large number and variety of cancers, thus providing cancer cell death and/or an inhibition of growth, elaboration and/or metastasis of the cancer, including remission and cure of the patient's cancer.
    Type: Grant
    Filed: February 23, 2021
    Date of Patent: March 5, 2024
    Assignee: YALE UNIVERSITY
    Inventors: David A. Spiegel, Charles E. Jakobsche
  • Patent number: 11917986
    Abstract: L-serine, L-serine precursors, L-serine derivatives and L-serine conjugates for treatment, amelioration and/or prevention of protein aggregation/tangles/plaques and diseases associated with protein aggregation/tangles/plaques. In particular, treatments and uses for L-serine, L-serine precursors, L-serine derivatives and L-serine conjugates include Alzheimer's disease (AD), Parkinson's disease, Amyotrophic Lateral Sclerosis (ALS), and Huntington disease (HD).
    Type: Grant
    Filed: March 28, 2014
    Date of Patent: March 5, 2024
    Assignee: THE INSTITUTE FOR ETHNOMEDICINE
    Inventors: Paul Alan Cox, Sandra Anne Banack, Deborah C. Mash
  • Patent number: 11920197
    Abstract: This disclosure provides oligomers, combinations of oligomers, compositions, kits, uses, and methods for detecting a C1orf43 nucleic acid, such as C1orf43 mRNA, such as human C1orf43 mRNA, in a sample.
    Type: Grant
    Filed: June 1, 2022
    Date of Patent: March 5, 2024
    Assignee: Gen-Probe Incorporated
    Inventors: Siobhán M. Miick, Paul M. Darby, Jo Ann Jackson, Damon Kittredge Getman
  • Patent number: 11921107
    Abstract: Disclosed is an assay device which comprises a liquid sample addition zone, a reagent zone, a detection zone, and a wicking zone, all defining a fluid flow path. The device further comprises a reagent addition zone along and in fluid communication with the fluid flow path downstream of the sample addition zone and upstream of the detection zone. An interrupting wash is added at this reagent addition zone in accordance with the method of the subject invention to control sample volume. The interrupting wash fluid is added at a predetermined fill volume on the chip device and also serves to wash the detection channel and fill the remaining chip volume.
    Type: Grant
    Filed: June 8, 2020
    Date of Patent: March 5, 2024
    Assignee: Ortho-Clinical Diagnostics, Inc.
    Inventors: Edward R. Scalice, Philip C. Hosimer, Zhong Ding, James D. Kanaley, David A. Tomasso, Daniel P. Salotto, Timothy C. Warren
  • Patent number: 11913951
    Abstract: Provided herein are high throughput methods for measuring the protease activity of the complement C3 convertase by detecting the consumption of C3 or the production of C3a in vivo and in vitro.
    Type: Grant
    Filed: March 21, 2019
    Date of Patent: February 27, 2024
    Assignee: Alexion Pharmaceuticals, Inc.
    Inventor: Christen D. Forbes
  • Patent number: 11913952
    Abstract: Provided herein are compositions and methods for detecting the binding of a peptide to an MHC molecule, and the binding of a peptide:MHC complex to a TCR. In preferred embodiments, the compositions and methods are in a highly-multiplexed way. The compositions and methods disclosed herein can be used to provide direct information on which peptides are bound to an MHC molecule. Also provided is a method for simultaneously detecting a large number of peptides for binding to an MHC molecule and/or a T cell. A method for detecting competitive binding of a large number of peptides to an MHC molecule and/or a T cell is also disclosed. Also provided herein is a method for simultaneously detecting a large number of specific TCRs. The compositions and methods of the present invention are useful for vaccine design, research and monitoring of autoimmune and infectious disease, immunogenicity testing of therapeutics, and tissue typing.
    Type: Grant
    Filed: November 22, 2021
    Date of Patent: February 27, 2024
    Assignee: Prognosys Biosciences, Inc.
    Inventors: John Andrew Altin, Mark S. Chee
  • Patent number: 11904003
    Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 102, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: March 17, 2023
    Date of Patent: February 20, 2024
    Assignee: Immatics Biotechnologies GMBH
    Inventors: Jens Hukelmann, Heiko Schuster, Ricarda Hannen, Christoph Schraeder, Jens Fritsche, Franziska Hoffgaard, Daniel Johannes Kowalewski, Oliver Schoor
  • Patent number: 11906524
    Abstract: The present subject matter provides urea biosensors as well as compositions, devices, and methods comprising such biosensors.
    Type: Grant
    Filed: November 19, 2016
    Date of Patent: February 20, 2024
    Assignee: Duke University
    Inventors: Homme W. Hellinga, Malin J. Allert
  • Patent number: 11899029
    Abstract: The present teachings provide apparatuses and methods for automated handling of samples, e.g., biological or chemical samples. The apparatuses and the methods of the present teachings allow automated performance of various sample manipulation steps without manual intervention. In a preferred embodiment, the present teachings provide apparatuses and methods for automated enrichment of templated beads produced by PCR.
    Type: Grant
    Filed: November 17, 2022
    Date of Patent: February 13, 2024
    Assignee: LIFE TECHNOLOGIES CORPORATION
    Inventors: Kristopher Barbee, Maximilian Carpino, Ray Wheeling, Nicholas Peter Bajka
  • Patent number: 11901085
    Abstract: The present embodiments relate generally to a system for improved storage of electronic health information, the system including: a computing device for receiving the electronic health information; and a server for communicating with the computing device, the server being accessible by the computing device at a first network location. The server can be configured to: receive a request from the computing device for a second network location, the second network location usable for storing the electronic health information, and the second network location being different from the first network location; determine the second network location; and provide the second network location to the computing device; and the computing device stores the electronic health information at the second network location.
    Type: Grant
    Filed: February 27, 2023
    Date of Patent: February 13, 2024
    Assignee: Ciarius Mobile Health Corp.
    Inventors: Trevor Stephen Hansen, Benjamin Eric Kerby, Dongkang Li, Shirui Yin
  • Patent number: 11899024
    Abstract: The invention relates generally to a process for isolating subpopulations of EVs to identify biomarkers useful identifying, determining the progression of, and/or prognosing a disease, including a neurological disease. More particularly, the present invention relates to detection technology of various exosomal biomarkers including proteins, protein modifications, sugars, RNA, DNA, lipids, and metabolites, and combinations thereof.
    Type: Grant
    Filed: July 12, 2018
    Date of Patent: February 13, 2024
    Assignee: Exosome Diagnostics, Inc.
    Inventors: Mia Sher, Erez Eitan, Christine Coticchia, Johan Karl Olov Skog, Robert Kitchen, Seth Yu
  • Patent number: 11899018
    Abstract: Described herein are methods, compositions and articles of manufacture involving neutral conjugated polymers including methods for synthesis of neutral conjugated water-soluble polymers with linkers along the polymer main chain structure and terminal end capping units. Such polymers may serve in the fabrication of novel optoelectronic devices and in the development of highly efficient biosensors. The invention further relates to the application of these polymers in assay methods.
    Type: Grant
    Filed: April 21, 2022
    Date of Patent: February 13, 2024
    Assignee: SIRIGEN II LIMITED
    Inventors: Brent S. Gaylord, Glenn P. Bartholomew, Russell A. Baldocchi, Janice W. Hong, William H. Huisman, Yongchao Liang, Trung Nguyen, Lan T. Tran, Jean M. Wheeler, Adrian Charles Vernon Palmer, Frank Peter Uckert
  • Patent number: 11890323
    Abstract: The invention features combination therapies using an IL-15-based superagonist complex and an antibody to effectively treat subjects with cancer and infectious diseases.
    Type: Grant
    Filed: December 9, 2022
    Date of Patent: February 6, 2024
    Assignee: Altor Bioscience, LLC
    Inventors: Bai Liu, Peter Rhode, Wenxin Xu, Hing C. Wong
  • Patent number: 11892457
    Abstract: Methods of detecting ZNT8 antibodies in serum are described. The methods include proteoliposomes comprising a transmembrane domain (TMD) and a cytosolic domain (CTD) of ZnT8 proteins exposed on the exterior of the proteoliposome; serum comprising antibodies targeting the ZnT8 proteins; and labelled captured autoantibodies that bind to ZnT8 antibodies.
    Type: Grant
    Filed: July 5, 2018
    Date of Patent: February 6, 2024
    Assignees: The Johns Hopkins University, The Board of Trustees of the Leland Stanford Junior University
    Inventors: Dax Fu, Chengfeng Merriman, Hongjie Dai, Hao Wan
  • Patent number: 11885814
    Abstract: A method for detecting the binding of a chromatin-associated factor of interest to a sequence of chromatin DNA in a cell, including: contacting a permeabilized cell or nucleus with a specific binding agent that specifically recognizes the chromatin-associated factor of interest, wherein the specific binding agent is linked to a nuclease that is inactive or an activatable transposome; activating the nuclease or transposase, thereby excising the sequence of chromatin DNA bound to the chromatin-associated factor of interest; isolating the excised DNA; and determining the sequence of the excised DNA, thereby detecting binding of a chromatin-associated factor of interest to a sequence of chromatin DNA in the cell.
    Type: Grant
    Filed: January 26, 2022
    Date of Patent: January 30, 2024
    Assignee: Fred Hutchinson Cancer Center
    Inventors: Steven Henikoff, Hatice Seda Kaya Okur, Terri Dawn Bryson, Peter James Skene
  • Patent number: 11887698
    Abstract: Systems and methods for building a comprehensive genome scale metabolic model. The method includes determining that at least one of a hypothetical profile annotation and an uncharacterized profile annotation is available in a profile annotation associated with a protein. Further, the method includes performing a machine learning procedure on at least one of the hypothetical profile annotation and the uncharacterized hypothetical profile annotation after a fuzzy string matching and ranking procedure. Further, the method includes obtaining all the possible protein annotations based on a fuzzy string matching procedure. Further, the method includes performing a rank procedure on at least one of the hypothetical profile annotation and the uncharacterized profile alternative annotation. Further, the method includes identifying all possible metabolic reactions for the protein annotation obtained by the fuzzy string matching procedure.
    Type: Grant
    Filed: September 29, 2020
    Date of Patent: January 30, 2024
    Assignee: SAMSUNG ELECTRONICS CO., LTD.
    Inventors: Rajasekhara Reddy Duvvuru Muni, Tadi Venkata Siva Kumar, Taeyong Kim
  • Patent number: 11887700
    Abstract: Techniques and apparatus for generating encoded representations of compounds are described. In one embodiment, for example, an apparatus may include at least one memory, and logic coupled to the at least one memory. The logic may be configured receive analytical information associated with at least one compound, generate at least one encoded representation of the at least one compound, the encoded representation comprising at least one segment representing at least one property of the at least one compound using a plurality of symbols. Other embodiments are described.
    Type: Grant
    Filed: May 4, 2020
    Date of Patent: January 30, 2024
    Assignee: WATERS TECHNOLOGIES IRELAND LIMITED
    Inventors: Steven J. Ciavarini, Curt Devlin, Patrick Brophy, Scott J. Geromanos
  • Patent number: 11884961
    Abstract: Provided herein are DNA-glycan conjugates that include a glycan and a covalently attached polynucleotide. The polynucleotide includes a plurality of modules. Each module includes a nucleotide string, and the plurality of modules includes a monomer module that corresponds to each carbohydrate monomer present in the DNA-glycan conjugate, and a linkage module that corresponds to each glycosidic linkage present between each carbohydrate monomer in the DNA-glycan conjugate. The nucleotide sequence of the plurality of modules corresponds to the glycan structure. Also provided herein are methods for making and using the DNA-glycan conjugates. Further provided is a computer-implemented method for translating data from a nucleotide sequence to a glycan structure, a system for converting data from a glycan structure to a nucleotide sequence, and a system for translating data from a nucleotide sequence to a glycan structure.
    Type: Grant
    Filed: June 1, 2018
    Date of Patent: January 30, 2024
    Assignee: GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC.
    Inventors: Peng George Wang, Jing Song, Muhammed Shukkoor Kondengaden, Aishwarya Parameswaran
  • Patent number: 11879004
    Abstract: Engineered antibodies that are stable and can be conjugated to a ligand or drug at a ligand/drug to antibody ratio of above 3, making these conjugates suitable for treatment of a variety of indications, are provided. Methods of producing these engineered antibodies are also provided.
    Type: Grant
    Filed: February 26, 2021
    Date of Patent: January 23, 2024
    Assignee: GENZYME CORPORATION
    Inventors: Qun Zhou, Sunghae Park, Huawei Qiu, Marie-Priscille Brun, Francis Duffieux
  • Patent number: 11878302
    Abstract: System, including methods and apparatus, for spacing droplets from each other and for detection of spaced droplets.
    Type: Grant
    Filed: September 2, 2021
    Date of Patent: January 23, 2024
    Assignee: Bio-Rad Laboratories, Inc.
    Inventors: George Carman, Thomas H. Cauley, III, David P. Stumbo
  • Patent number: 11874273
    Abstract: The present invention pertains to a polyclonal or monoclonal antibody specifically binding to BoNT/E-cleaved SNAP-25.
    Type: Grant
    Filed: December 15, 2020
    Date of Patent: January 16, 2024
    Inventors: Cornelia Bruenn, Gerd Mander
  • Patent number: 11873533
    Abstract: Disclosed is a method of detecting and quantifying genomic and gene expression alterations using RNA in a biological sample. The disclosed method may include determining presence or absence of the genomic alteration and/or determining presence or absence of the gene expression and/or quantifying the level of the gene expression, by performing variant calling of the sequence alignment obtained from the disclosed method. Variant calling may comprise the steps of identifying differences between a consensus read and a reference genome based on the sequence alignment from the disclosed method; and determining the read count of sequence alignments comprising genomic alteration. The genomic alteration may be an insertion (such as a duplication), a deletion, a single nucleotide variant, or combinations thereof. Also disclosed is a kit for detecting and quantifying genomic and gene expression alterations using RNA in a biological sample.
    Type: Grant
    Filed: May 26, 2022
    Date of Patent: January 16, 2024
    Assignee: LUCENCE LIFE SCIENCES PTE. LTD.
    Inventors: Yukti Choudhury, Chae Yin Cher, Jia Min Ho, Min-Han Tan, Kao Chin Ngeow, Pannapa Pinweha
  • Patent number: 11874226
    Abstract: A computer-implemented method includes controlling an instrument to measure a fluorescence emission spectrum of a sample including a first peak emission wavelength and at least a second peak emission wavelength, emitted in response to an excitation wavelength and controlling the instrument to measure an absorbance obtained at the excitation wavelength of the sample. The method may include determining, using the computer, a ratio of the measurements at either the second peak emission wavelength, or a sum of measurements at a plurality of peak emission wavelengths including at least the first peak emission wavelength and the second peak emission wavelength, to the first peak emission wavelength, and calculating, using the computer, a value for a quality parameter based on a combination of at least the ratio and the absorbance measurement. The method may include controlling an associated process based on the quality parameter.
    Type: Grant
    Filed: May 4, 2021
    Date of Patent: January 16, 2024
    Assignees: HORIBA INSTRUMENTS INCORPORATED, HORIBA ADVANCED TECHNO CO., LTD.
    Inventor: Adam Matthew Gilmore
  • Patent number: 11873528
    Abstract: The present invention is directed to methods, compositions and systems for analyzing sequence information while retaining structural and molecular context of that sequence information.
    Type: Grant
    Filed: September 12, 2022
    Date of Patent: January 16, 2024
    Assignee: 10x Genomics, Inc.
    Inventors: Xinying Zheng, Serge Saxonov, Michael Schnall-Levin, Kevin Ness, Rajiv Bharadwaj
  • Patent number: 11873331
    Abstract: Monoclonal antibodies or fragments thereof are disclosed, which are binding to the protein P of the human Respiratory Syncytial Virus (RSV) which has a variable region of the heavy chain which has a sequence with at least a 90%, 95% or 99% of identity with the SEQ ID No: 1 or SEQ ID 5 or a variable region of the light chain which has a sequence with at least a 90%, 95% or 99% of identity with the SEQ ID No:2 or SEQ ID No: 6. Also provided are diagnostic methods ex vivo or in vitro for detection of the viral antigen P of RSV, in which are used the monoclonal antibodies produced and secreted by the hybridomas 2E6/D2 and 6H5/H1. The invention can be used in detection for RSV kits, having the antibodies produced by the mentioned hybridomas.
    Type: Grant
    Filed: November 2, 2020
    Date of Patent: January 16, 2024
    Assignee: PONTIFICIA UNIVERSIDAD CATOLICA DE CHILE
    Inventors: Susan Marcela Bueno Ramirez, Alexis Mikes Kalergis Parra, Jorge Eugenio Mora Alarcon
  • Patent number: 11874214
    Abstract: A biosensor is provided including a detection device and a flow cell mounted to the detection device. The detection device has a detector surface with a plurality of reaction sites. The detection device also includes a filter layer. A method is providing including obtaining signal data from an array of light detectors; determining a crosstalk function for each of the light detectors of the array of light detectors; and determining characteristics of analytes of interest based on the signal data using the crosstalk functions.
    Type: Grant
    Filed: March 7, 2023
    Date of Patent: January 16, 2024
    Assignee: ILLUMINA, INC.
    Inventors: Helmy A. Eltoukhy, Robert C. Kain, Wenyi Feng, Mark Pratt, Bernard Hirschbein, Poorya Sabounchi, Tarun Khurana
  • Patent number: 11866484
    Abstract: The invention relates to the identification of a highly stable single domain antibody scaffold (hs2dAb) and its use in generating synthetic single domain antibody library (hs2dAb-L1). The invention also relates to antigen-binding proteins comprising said stable single domain antibody scaffold and their uses, in particular as therapeutics.
    Type: Grant
    Filed: March 3, 2021
    Date of Patent: January 9, 2024
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), INSTITUT CURIE, UNIVERSITE PAUL SABATIER TOULOUSE III, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
    Inventors: Aurelien Olichon, Sandrine Moutel, Franck Perez
  • Patent number: 11866489
    Abstract: An isolated anti-SCUBE2 antibody or a binding fragment thereof is disclosed. The anti-SCUBE2 antibody comprises an antigen binding region that specifically binds to a target domain located within SCUBE2 (SEQ ID NO: 66) and exhibits a property of inhibiting VEGF-induced angiogenesis. The target domain is selected from the group consisting of the EGF-like motifs 4 to 6 ranging from a.a. position 175 to 323, or the spacer region ranging from a.a. position 441 to 659, or the first cys-rich motif ranging from a.a. position 668 to 725 of SCUBE2 (SEQ ID NO: 66). The anti-SCUBE2 antibody or binding fragment thereof is for use in treating a disease associated with VEGF-induced angiogenesis, or for use in treating a tumor or inhibiting tumor angiogenesis and cancer cell growth in a subject in need thereof.
    Type: Grant
    Filed: June 8, 2021
    Date of Patent: January 9, 2024
    Assignee: ACADEMIA SINICA
    Inventors: Ruey-Bing Yang, Yuh-Charn Lin
  • Patent number: 11857326
    Abstract: Provided herein are a variety of neural probe devices that include an agent delivery feature via an agent coating or an agent delivery mechanism of some kind. The probe devices can include depth or cortical probes or electrodes. The agent delivery mechanisms can include, for example, a dissolvable agent delivery structure, an agent delivery lumen, a magnetically deployable cover, an iontophoretic delivery mechanism, an agent delivery cavity defined in the neural probe, or an agent reservoir with an actuable gate.
    Type: Grant
    Filed: March 9, 2020
    Date of Patent: January 2, 2024
    Assignee: NeuroOne Medical Technologies Corporation
    Inventors: Dave Rosa, Thomas Bachinski
  • Patent number: 11862295
    Abstract: A system and method for classifying conformers of a molecule are provided. The methods for classifying conformers of a molecule include selecting a target molecule, generating a list of conformers of the target molecule, completing a quantum mechanics (QM) simulation for each conformer, extracting an electronic energy for each conformer from the corresponding QM simulation, calculating average electron density (AED) values corresponding to a most electronegative group of the target molecule, generating a plot of the electronic energies vs. the calculated AED values, and classifying conformers based on this plot. Similar methods can also be used to predict shapes of electrostatic potential (ESP) maps for conformers of a molecule. These ESP maps can, in turn, be used to identify conformers of the molecule having desired chemical or pharmaceutical properties.
    Type: Grant
    Filed: November 8, 2022
    Date of Patent: January 2, 2024
    Assignee: UNITED ARAB EMIRATES UNIVERSITY
    Inventor: Alya A. Arabi
  • Patent number: 11857612
    Abstract: Combination therapeutics for the treatment of cancer include the use of immune effector cells, IL-15 based superagonists and one or more immunotherapeutic agents such as Bacillus Calmette-Guerin (BCG).
    Type: Grant
    Filed: December 15, 2022
    Date of Patent: January 2, 2024
    Assignee: NantCell, Inc.
    Inventor: Patrick Soon-Shiong
  • Patent number: 11858987
    Abstract: An objective of the present invention is to obtain two types of substantively homogeneous cancer stem cell populations which can be characterized using the cell surface marker Lgr5, and to provide cancer therapeutics using an antibody against a cell membrane molecule specifically expressed in these cancer stem cells by identifying said cell membrane molecule. A further objective is to provide, using an antibody against a cell membrane molecule specifically expressed in cancer stem cells, a reagent for detecting cancer stem cells, and a method for diagnosing and sorting cancer patients. The present inventors discovered that highly pure large intestine cancer stem cells (CSC) can be obtained in a large quantity, and identified the two types of conditions of large intestine CSCs distinguishable through Lgr5 expression. Moreover, the present inventors discovered that an antibody against a cell membrane molecule specifically expressed in said cancer stem cells can damage said cells.
    Type: Grant
    Filed: June 26, 2020
    Date of Patent: January 2, 2024
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Tatsumi Yamazaki, Hisafumi Okabe, Shinta Kobayashi, Takeshi Watanabe, Koichi Matsubara, Osamu Natori, Atsuhiko Kato, Masami Suzuki
  • Patent number: 11858984
    Abstract: Provided is a substance capable of effectively suppressing cancer metastasis or a pharmaceutical composition that effectively acts on an inflammatory disease. The pharmaceutical composition is a pharmaceutical composition containing, as an active ingredient, an antibody or an antibody fragment thereof having antigen-binding activity for an S100A8/A9 heterodimer, and blocks interaction between S100A8/A9 and a group of receptors therefor, to thereby strongly suppress cancer metastasis both in vitro and in vivo, or alleviate inflammation. That is, the anti-S100A8/A9 antibody or the antibody fragment thereof can strongly suppress cancer metastasis or alleviate inflammation, by virtue of its blocking action on the interaction between S100A8/A9 and the group of receptors therefor.
    Type: Grant
    Filed: April 15, 2019
    Date of Patent: January 2, 2024
    Assignees: National University Corporation Okayama University, Niigata University, National University Corporation Gunma University
    Inventors: Masakiyo Sakaguchi, Shinichi Toyooka, Shuta Tomida, Kazuhiko Shien, Hiroki Sato, Rie Kinoshita, Junichiro Futami, Kota Araki, Mikio Okazaki, Eisaku Kondo, Yusuke Inoue, Akira Yamauchi
  • Patent number: 11851712
    Abstract: Methods for increasing immune therapy response and predicting likelihood of cancer metastasis by analyzing the expression of genes associated with replication stress response. In some aspects, cancers are treated with immune checkpoint inhibitors and/or MEK inhibitors. Methods for selecting patients by analyzing the expression of genes associated with a defect in replication stress response are also provided.
    Type: Grant
    Filed: March 6, 2019
    Date of Patent: December 26, 2023
    Assignee: Board of Regents, The University of Texas System
    Inventors: Daniel McGrail, Shiaw-Yih Lin, Patrick Pilie, Eric Jonasch, Curtis Chun-Jen Lin
  • Patent number: 11850247
    Abstract: The invention provides a compound of formula I, formula II, or formula III: or a salt thereof, wherein R1-R10 have any of the values described in the specification, as well as compositions comprising a compound of formula I. The compounds are useful as HIV-1 CA-targeting molecules and as antiviral agents.
    Type: Grant
    Filed: April 5, 2021
    Date of Patent: December 26, 2023
    Assignees: REGENTS OF THE UNIVERSITY OF MINNESOTA, EMORY UNIVERSITY
    Inventors: Zhengqiang Wang, Stefanos G. Sarafianos
  • Patent number: 11851475
    Abstract: Disclosed is a membrane-type metalloprotease inhibitory protein T1Pr?TACE and use thereof, which can be used for preparing drugs targeting MT1-MMP or TACE endonuclease. Also disclosed are an antitumor pharmaceutical composition comprising BHK-21 cells and an artificial basal membrane which expresses T1Pr?TACE protein.
    Type: Grant
    Filed: December 20, 2018
    Date of Patent: December 26, 2023
    Assignee: XI'AN JIAOTONG-LIVERPOOL UNIVERSITY
    Inventors: Meng Huee Lee, Bingjie Jiang, Jian Liu
  • Patent number: 11851698
    Abstract: The present invention relates to a method for detecting a pathogen in cellular lysate by measuring pathogen-specific enzyme activity. The method comprises contacting the cellular lysate with a substrate the pathogen of interest recognizes and modifies, and obtaining a measurable, recordable, signal. The method may comprise detection of SARS-CoV viruses using the activity of SARS PLpro enzyme in tongue scrape lysate as a readout.
    Type: Grant
    Filed: February 5, 2023
    Date of Patent: December 26, 2023
    Assignee: MESA PHOTONICS, LLC
    Inventors: Frauke Henrike Rininsland, Daniel James Kane
  • Patent number: 11850592
    Abstract: A cell sorting device is disclosed, wherein the device includes a sorting magnet and at least one particle manipulation device, wherein the particle manipulation device is formed on a surface of a fabrication substrate. The device may include at least one fluid channel, wherein the sorting magnet and the particle manipulation device are in fluid communication with one another through at least one fluid channel. A method of sorting cells from a first cell suspension is also disclosed, The method may include a) magnetic labeling of first target cells and removal of the non-target cells by applying magnetic fields to obtain a second cell suspension; b) fluorescence-activated labeling of second target cells present in the second cell suspension and separating the fluorescence-activated second target cells from the not labeled cells to obtain a third cell suspension.
    Type: Grant
    Filed: February 11, 2020
    Date of Patent: December 26, 2023
    Assignee: Owl biomedical, Inc.
    Inventors: John S. Foster, Kevin Shields, Mehran Hoonejani
  • Patent number: 11846642
    Abstract: The present invention provides a sensitive and specific indirect homogeneous mobility shift assay using size exclusion chromatography to measure biologics such as vedolizumab and ustekinumab in a patient sample. The assays of the present invention are particularly advantageous for detecting the presence or level of biologics that target complex or large antigens including cell surface proteins, transmembrane proteins, heavily glycosylated proteins, and multimeric proteins, as well as antigens that cannot be purified, impure antigens, and partially or substantially purified antigens. The present invention also provides isolated soluble ?4?7 integrin heterodimers and isolated soluble IL-12p40 monomers that are suitable for use in the indirect assays described herein.
    Type: Grant
    Filed: August 9, 2019
    Date of Patent: December 19, 2023
    Assignee: Prometheus Laboratories Inc.
    Inventors: Jared Salbato, Stefan Westin, Nicholas Chi-Kwan Ling, Anjali Jain, Sharat Singh
  • Patent number: 11848107
    Abstract: Systems and methods are provided for predicting metastasis of a cancer in a subject. A plurality of data elements for the subject's cancer is obtained, including sequence features comprising relative abundance values for gene expression in a cancer biopsy of the subject, optional personal characteristics about the subject, and optional clinical features related to the stage, histopathological grade, diagnosis, symptom, comorbidity, and/or treatment of the cancer in the subject, and/or a temporal element associated therewith. One or more models are applied to the plurality of data elements, determining one or more indications of whether the cancer will metastasize. A clinical report comprising the one or more indications is generated.
    Type: Grant
    Filed: December 21, 2021
    Date of Patent: December 19, 2023
    Assignee: Tempus Labs, Inc.
    Inventors: Ashraf Hafez, Martin Christian Stumpe, Nike Beaubier, Daniel Neems, Caroline Epstein, Adrian William George Lange
  • Patent number: 11846032
    Abstract: Catalyst systems employing inexpensive and readily-available protic co-catalysts to increase a proton reduction rate in a hydrogen evolution reaction (HER) are described herein. The protic co-catalysts function to increase the rate without being consumed in the process of water splitting to hydrogen and oxygen. They may simultaneously serve to stabilize the pH of the water and be the electrolyte to carry the current for the electrolytic splitting of water. The protic co-catalysts also decrease the overpotential energy requirement for the process of water splitting. These protic co-catalysts can be used with both heterogeneous and homogenous catalysts, as well as assist photocatalysis and other processes for the reduction of protons.
    Type: Grant
    Filed: December 11, 2018
    Date of Patent: December 19, 2023
    Assignee: ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA
    Inventors: Dennis Lichtenberger, Richard S. Glass, Dong-Chul Pyun, William Brezinski, Kayla Clary, Metin Karayilan
  • Patent number: 11840743
    Abstract: The present disclosure provides methods to identify peptides and small molecule moieties that are able to modulate protein-protein interactions (PPIs). Some moieties can disrupt specific PPIs within a complex, or disrupt variant-specific PPIs. Some moieties can alternatively bridge between two proteins in a protein-specific or a variant-specific manner. The methods described enable generation of compounds able to modulate PPI networks within cells with implications for drug development for pathological conditions.
    Type: Grant
    Filed: May 13, 2020
    Date of Patent: December 12, 2023
    Assignee: SYNTHEX, INC.
    Inventors: Maria Soloveychik, Charly Chahwan